In a filing, Terns Pharmaceuticals Inc revealed its Chief Medical Officer Kuriakose Emil unloaded Company’s shares for reported $3640.0 on Jul 01 ’25. In the deal valued at $4.27 per share,853 shares were sold. As a result of this transaction, Kuriakose Emil now holds 52,464 shares worth roughly $0.37 million.
Then, Gengos Andrew bought 10,000 shares, generating $39,283 in total proceeds. Upon buying the shares at $3.93, the Chief Financial Officer now owns 25,000 shares.
Before that, Burroughs Amy L. bought 23,314 shares. Terns Pharmaceuticals Inc shares valued at $90,230 were divested by the Chief Executive Officer at a price of $3.87 per share. As a result of the transaction, Burroughs Amy L. now holds 47,083 shares, worth roughly $0.34 million.
A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in late February with a ‘”a Mkt perform”‘ rating. Oppenheimer began covering TERN with “an Outperform” recommendation on October 31, 2024. Mizuho started covering the stock on June 22, 2023. It rated TERN as “a Buy”.
Price Performance Review of TERN
On Monday, Terns Pharmaceuticals Inc [NASDAQ:TERN] saw its stock fall -1.38% to $7.13. Over the last five days, the stock has lost -2.06%. Terns Pharmaceuticals Inc shares have fallen nearly -33.24% since the year began. Nevertheless, the stocks have risen 28.70% over the past one year.
How much short interest is there in Terns Pharmaceuticals Inc?
A steep rise in short interest was recorded in Terns Pharmaceuticals Inc stocks on 2025-08-29, growing by 1.13 million shares to a total of 7.86 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 6.73 million shares. There was a rise of 14.36%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 07, 2023 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $18 price target.
